Janux Therapeutics (JANX) director McNulty received 3,750 shares

Insider transactions reported

Alana B. McNulty (director at Janux Therapeutics Inc., JANX) reported that they received 3,750 shares on Jun 11, 2025. After these transactions the filing shows 6,250 shares held directly.

Reporting person

McNulty Alana B.

Options and other derivatives

Holdings before and after

• Common Stock: 2,500 to 6,250 direct
• Stock Option (right to buy): 0 to 11,667 direct

Footnotes from the filing

1. 1. Represents the grant of restricted stock units ( RSUs ), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
2. 2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ